Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte Activation Gene 3 (LAG-3), also known as CD223, is a transmembrane protein and immune checkpoint receptor with a central role in regulating T cell function and immune homeostasis. It delivers inhibitory signals that regulate immune cell homeostasis, activation and proliferation of T cells, cytokine production, and cytolytic activity of effector lymphocytes. Persistent expression of LAG-3 contributes to dysfunctional cytotoxic lymphocytes in cancer or chronic infection, making it a target for cancer immunotherapy and autoimmune disease therapies.
Anti-LAG-3 antibodies block the interaction of LAG-3 with its ligand MHC class II, thereby reversing LAG-3 mediated inhibition of T cell function and enhancing anti-tumor immunity. Fusion proteins act similarly by binding LAG-3 and preventing its inhibitory signaling.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte Activation Gene 3 (LAG-3).